Skip to main content
Navamedic logo

Navamedic — Investor Relations & Filings

Ticker · NAVA ISIN · NO0010205966 LEI · 529900LKVQOR2SRUJU71 OL Wholesale and retail trade
Open in API
Filings indexed 825 across all filing types
Latest filing 2023-03-03 Major Shareholding Noti…
Country NO Norway
Listing OL NAVA

About Navamedic

https://navamedic.com/

Navamedic is a pharmaceutical company that develops, produces, and commercializes a diverse portfolio of medicines and related health products. The company's offerings include specialty pharmaceuticals, branded generics, and consumer health items. Its product portfolio addresses various medical needs, with treatments for conditions such as obesity, Parkinson's disorder, and inborn errors of metabolism, in addition to antibiotics. Serving as a reliable supplier and distribution partner, Navamedic provides high-quality products to hospitals and pharmacies, with a strong presence in the Nordic region and the Netherlands. The company focuses on improving patient outcomes through innovations, including advancements in personalized treatment for Parkinson's care.

Recent filings

Filing Released Lang Actions
Flagging notification Navamedic ASA
Major Shareholding Notification Classification · 99% confidence The document is a short notification regarding a change in shareholding percentage (6.65959%) by Futur Pension Holding AB in Navamedic ASA. This directly relates to changes in significant share ownership crossing a threshold, which aligns with the definition of Major Shareholding Notification (MRQ). The document is very short and serves as a direct notification of this change.
2023-03-03 English
NAVAMEDIC ASA: GRANT OF OPTIONS TO PRIMARY INSIDERS
Director's Dealing Classification · 100% confidence The document text consists of structured tables detailing transactions involving 'person discharging managerial responsibilities' (executives/directors) at Navamedic ASA. Specifically, it reports the 'Grant/acceptance of options' by the CEO, CFO, and CBDO. This type of mandatory disclosure regarding personal share transactions by company directors and executives is classified as Director's Dealing.
2023-02-16 English
NAVAMEDIC ASA: GRANT OF OPTIONS TO PRIMARY INSIDERS
Remuneration Information Classification · 99% confidence The document explicitly announces the 'GRANT OF OPTIONS TO PRIMARY INSIDERS' (executive management) under a long-term incentive program. It details the number of options granted, the exercise price, vesting schedule, and the resulting holdings of specific primary insiders (CEO, CFO, etc.). This content directly relates to insider transactions and executive compensation/incentives, but specifically focuses on the granting of options, which is a form of share issuance/capital change or insider dealing. Given the options are granted to directors/executives, it falls under insider activity. However, the most precise category for reporting personal share transactions by directors and executives is 'Director's Dealing' (DIRS). While it's an option grant rather than a direct purchase/sale, in many regulatory contexts, significant option grants to insiders are reported alongside insider dealings. Reviewing the definitions, 'Director's Dealing' (DIRS) covers 'Report of personal share transactions by company directors and executives (insider trades)'. Since this is a grant to primary insiders, DIRS is the most appropriate fit among the specific options, although 'Share Issue/Capital Change' (SHA) is also related to the issuance aspect. Given the focus on 'primary insiders' and the nature of the disclosure (MAR Article 19), DIRS is the standard classification for reporting insider transactions/grants.
2023-02-16 English
Navamedic ASA: Q4 2022 financial results
Investor Presentation Classification · 95% confidence The document is a presentation titled 'Fourth quarter 2022 results Navamedic ASA' dated 16 February 2023. It contains detailed financial tables (P&L, Balance Sheet, Cash Flow), strategic business updates, and market analysis. While it presents financial results, the format is clearly a slide deck intended for investors, as evidenced by the visual layout, bullet points, and 'Thank you for your attention' closing. It is not a full quarterly report (IR) but rather an investor presentation (IP) summarizing the quarterly performance. Q4 2022
2023-02-16 Norwegian
Navamedic ASA: Q4 2022 financial results
Earnings Release Classification · 100% confidence The document explicitly announces the 'Q4 2022 financial results' for Navamedic ASA, providing key financial metrics (revenues, gross margin, EBIT) for the quarter and the full year 2022. This content structure—a summary of period-specific financial performance—is characteristic of an Earnings Release (ER). Although it mentions an attached presentation, the primary content provided is the summary of the results themselves, making ER the most appropriate classification over RPA or CT. It is not a comprehensive annual report (10-K) or a detailed interim report (IR), as it focuses on the immediate release of period results. Q4 2022
2023-02-16 English
Navamedic ASA: Resultater for fjerde kvartal 2022
Investor Presentation Classification · 95% confidence The document is a presentation titled 'Fourth quarter 2022 results Navamedic ASA' dated 16 February 2023. It contains detailed financial tables (P&L, Balance Sheet, Cash Flow), strategic business updates, and market analysis. While it presents financial results, the format is clearly a slide deck intended for investors, as evidenced by the visual layout, bullet points, and 'Thank you for your attention' closing. It is not a full quarterly report (IR) but rather an investor presentation (IP) summarizing the quarterly performance. Q4 2022
2023-02-16 Norwegian

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.